Anesth Pain Med.  2022 Apr;17(2):145-156. 10.17085/apm.22145.

Anesthetic care for electroconvulsive therapy

• Joung KW
• Park DH
• Jeong CY
• Yang HS

• KMID: 2531690
• DOI: http://doi.org/10.17085/apm.22145

Abstract

Counselling and medication are often thought of as the only interventions for psychiatric disorders, but electroconvulsive therapy (ECT) has also been applied in clinical practice for over 80 years. ECT refers to the application of an electric stimulus through the patient’s scalp to treat psychiatric disorders such as treatment-resistant depression, catatonia, and schizophrenia. It is a safe, effective, and evidence-based therapy performed under general anesthesia with muscle relaxation. An appropriate level of anesthesia is essential for safe and successful ECT; however, little is known about this because of the limited interest from anesthesiologists. As the incidence of ECT increases, more anesthesiologists will be required to better understand the physiological changes, complications, and pharmacological actions of anesthetics and adjuvant drugs. Therefore, this review focuses on the fundamental physiological changes, management, and pharmacological actions associated with various drugs, such as anesthetics and neuromuscular blocking agents, as well as the comorbidities, indications, contraindications, and complications of using these agents as part of an ECT procedure through a literature review and our own experiences.

Keyword

Anesthesia; Electroconvulsive therapy; Experience; Major psychiatric disorders

Reference

1. Ding Z, White PF. Anesthesia for electroconvulsive therapy. Anesth Analg. 2002; 94:1351–64.

2. Khan A, Mirolo MH, Hughes D, Bierut L. Electroconvulsive therapy. Psychiatr Clin North Am. 1993; 16:497–513.

3. McCall WV, Kellner CH, Fink M. Convulsive therapy and the Journal of ECT: 30 years of publication and continuing. J ECT. 2014; 30:1–2.

4. Taylor S. Electroconvulsive therapy: a review of history, patient selection, technique, and medication management. South Med J. 2007; 100:494–8.

5. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry. 2004; 55:301–12.

6. Food and Drug Administration, HHS. Neurological devices; reclassification of electroconvulsive therapy devices; effective date of requirement for premarket approval for electroconvulsive therapy devices for certain specified intended uses. Final order. Fed Regist. 2018; 83:66103–24.

7. Hermann RC, Dorwart RA, Hoover CW, Brody J. Variation in ECT use in the United States. Am J Psychiatry. 1995; 152:869–75.

8. Wang G, Han C, Liu CY, Chan S, Kato T, Tan W, et al. Management of treatment-resistant depression in real-world clinical practice settings across Asia. Neuropsychiatr Dis Treat. 2020; 16:2943–59.

9. Xiang YT, Ungvari GS, Correll CU, Chiu HF, Lai KY, Wang CY, et al. Use of electroconvulsive therapy for Asian patients with schizophrenia (2001-2009): trends and correlates. Psychiatry Clin Neurosci. 2015; 69:489–96.

10. Lee JR, Park SJ, Lim JG, Yang HS. Ambulatory anesthetic care for electroconvulsive therapy (ECT) in psychiatric patients. Korean J Anesthesiol. 2002; 43:520–4.

11. Jaffe R. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging: a task force report of the American Psychiatric Association, 2nd ed. Am J Psychiatry. 2002; 159:331.

12. Fink M, Kellner CH, McCall WV. Optimizing ECT technique in treating catatonia. J ECT. 2016; 32:149–50.

13. Shapira B, Calev A, Lerer B. Optimal use of electroconvulsive therapy: choosing a treatment schedule. Psychiatr Clin North Am. 1991; 14:935–46.

14. Gill SP, Kellner CH. Clinical practice recommendations for continuation and maintenance electroconvulsive therapy for depression: outcomes from a review of the evidence and a consensus workshop held in Australia in May 2017. J ECT. 2019; 35:14–20.

15. Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015; 16:76–95.

16. Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015; 49:1087–206.

17. Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatry. 2016; 61:561–75.

18. Franklin AD, Sobey JH, Stickles ET. Anesthetic considerations for pediatric electroconvulsive therapy. Paediatr Anaesth. 2017; 27:471–9.

19. Rasmussen K. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (second edition). J ECT. 2002; 18:58–9.

20. Sundsted KK, Burton MC, Shah R, Lapid MI. Preanesthesia medical evaluation for electroconvulsive therapy: a review of the literature. J ECT. 2014; 30:35–42.

21. Tess AV, Smetana GW. Medical evaluation of patients undergoing electroconvulsive therapy. N Engl J Med 2009; 360: 1437-44. Erratum in. N Engl J Med. 2011; 364:1582.

22. Thompson JW, Weiner RD, Myers CP. Use of ECT in the United States in 1975, 1980, and 1986. Am J Psychiatry. 1994; 151:1657–61.

23. Wagner KJ, Möllenberg O, Rentrop M, Werner C, Kochs EF. Guide to anaesthetic selection for electroconvulsive therapy. CNS Drugs. 2005; 19:745–58.

24. Lafferty JE, North CS, Spitznagel E, Isenberg K. Laboratory screening prior to ECT. J ECT. 2001; 17:158–65.

25. Cristancho MA, Alici Y, Augoustides JG, O'Reardon JP. Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician. Curr Psychiatry Rep. 2008; 10:474–80.

26. Fernández-Candil J, Castelltort Mascó L, Fàbregas Julià N, Urretavizcaya Sarachaga M, Bernardo Arroyo M, Valero Castell R. Anaesthesia in electroconvulsive therapy. Special conditions. Rev Psiquiatr Salud Ment (Engl Ed). 2020; 13:36–46.

27. Weinger MB, Partridge BL, Hauger R, Mirow A. Prevention of the cardiovascular and neuroendocrine response to electroconvulsive therapy: I. Effectiveness of pretreatment regimens on hemodynamics. Anesth Analg. 1991; 73:556–62.

28. Castelli I, Steiner LA, Kaufmann MA, Alfillé PH, Schouten R, Welch CA, et al. Comparative effects of esmolol and labetalol to attenuate hyperdynamic states after electroconvulsive therapy. Anesth Analg. 1995; 80:557–61.

29. Wells DG, Davies GG. Hemodynamic changes associated with electroconvulsive therapy. Anesth Analg. 1987; 66:1193–5.

30. Mental Health and Drug and Alcohol Office. Guidelines: ECT minimum standards of practice in NSW / NSW Health. North Sydney: Mental Health and Drug and Alcohol Office;2010.

31. Larsen JR, Hein L, Strömgren LS. Ventricular tachycardia with ECT. J ECT. 1998; 14:109–14.

32. Price JW, Price JR, Perry TL. Excessive hypertension and pulmonary edema after electroconvulsive therapy. J ECT. 2005; 21:174–7.

33. Ring BS, Parnass SM, Shulman RB, Phelan J, Khan SA. Cardiogenic shock after electroconvulsive therapy. Anesthesiology. 1996; 84:1511–3.

34. Saito S, Kadoi Y, Iriuchijima N, Obata H, Arai K, Morita T, et al. Reduction of cerebral hyperemia with anti-hypertensive medication after electroconvulsive therapy. Can J Anaesth. 2000; 47:767–74.

35. Saito S, Miyoshi S, Yoshikawa D, Shimada H, Morita T, Kitani Y. Regional cerebral oxygen saturation during electroconvulsive therapy: monitoring by near-infrared spectrophotometry. Anesth Analg. 1996; 83:726–30.

36. Nott MR, Watts JS. A fractured hip during electro-convulsive therapy. Eur J Anaesthesiol. 1999; 16:265–7.

37. Sarpel Y, Toğrul E, Herdem M, Tan I, Baytok G. Central acetabular fracture-dislocation following electroconvulsive therapy: report of two similar cases. J Trauma. 1996; 41:342–4.

38. Edwards RM, Stoudemire A, Vela MA, Morris R. Intraocular pressure changes in nonglaucomatous patients undergoing electroconvulsive therapy. Convuls Ther. 1990; 6:209–13.

39. McCormick AS, Saunders DA. Oxygen saturation of patients recovering from electroconvulsive therapy. Anaesthesia. 1996; 51:702–4.

40. Labbate LA, Miller JP. Midazolam for treatment of agitation after ECT. Am J Psychiatry. 1995; 152:472–3.

41. Narang P, Ianovich F, Sarai SK, Lippmann S. Benefits of dexmedetomidine in management of post-ECT agitation. J ECT. 2017; 33:150–1.

42. Stein ALS, Sacks SM, Roth JR, Habis M, Saltz SB, Chen C. Anesthetic management during electroconvulsive therapy in children: a systematic review of the available literature. Anesth Analg. 2020; 130:126–40.

43. Wachtel LE. Treatment of catatonia in autism spectrum disorders. Acta Psychiatr Scand. 2019; 139:46–55.

44. Gilot B, Gonzalez D, Bournazeau JA, Barriére A, Van Lieferinghen P. [Case report: electroconvulsive therapy during pregnancy]. Encephale. 1999; 25:590–4. French.

45. Rose S, Dotters-Katz SK, Kuller JA. Electroconvulsive therapy in pregnancy: safety, best practices, and barriers to care. Obstet Gynecol Surv. 2020; 75:199–203.

46. Echevarría Moreno M, Martin Muñoz J, Sanchez Valderrabanos J, Vázquez Gutierrez T. Electroconvulsive therapy in the first trimester of pregnancy. J ECT. 1998; 14:251–4.

47. Brown NI, Mack PF, Mitera DM, Dhar P. Use of the ProSeal laryngeal mask airway in a pregnant patient with a difficult airway during electroconvulsive therapy. Br J Anaesth. 2003; 91:752–4.

48. Leiknes KA, Cooke MJ, Jarosch-von Schweder L, Harboe I, Høie B. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Arch Womens Ment Health. 2015; 18:1–39.

49. Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19: guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetists. Anaesthesia. 2020; 75:785–99.

50. Gil-Badenes J, Valero R, Valentí M, Macau E, Bertran MJ, Claver G, et al. Electroconvulsive therapy protocol adaptation during the COVID-19 pandemic. J Affect Disord. 2020; 276:241–8.

51. Ramakrishnan VS, Kim YK, Yung W, Mayur P. ECT in the time of the COVID-19 pandemic. Australas Psychiatry. 2020; 28:527–9.

52. Luccarelli J, Fernandez-Robles C, Fernandez-Robles C, Horvath RJ, Berg S, McCoy TH, et al. Modified anesthesia protocol for electroconvulsive therapy permits reduction in aerosol-generating bag-mask ventilation during the COVID-19 pandemic. Psychother Psychosom. 2020; 89:314–9.

53. Limoncelli J, Marino T, Smetana R, Sanchez-Barranco P, Brous M, Cantwell K, et al. General anesthesia recommendations for electroconvulsive therapy during the Coronavirus disease 2019 pandemic. J ECT. 2020; 36:152–5.

54. MacPherson RD. Which anesthetic agents for ambulatory electro-convulsive therapy? Curr Opin Anaesthesiol. 2015; 28:656–61.

55. Avramov MN, Husain MM, White PF. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy. Anesth Analg. 1995; 81:596–602.

56. Cook A, Stevenson G, Scott AI. A survey of methohexitone use by anesthetists in the clinical practice of ECT in Edinburgh. J ECT. 2000; 16:350–5.

57. Mokriski BK, Nagle SE, Papuchis GC, Cohen SM, Waxman GJ. Electroconvulsive therapy-induced cardiac arrhythmias during anesthesia with methohexital, thiamylal, or thiopental sodium. J Clin Anesth. 1992; 4:208–12.

58. Saito S, Kadoi Y, Nara T, Sudo M, Obata H, Morita T, et al. The comparative effects of propofol versus thiopental on middle cerebral artery blood flow velocity during electroconvulsive therapy. Anesth Analg. 2000; 91:1531–6.

59. Tanaka N, Saito Y, Hikawa Y, Nakazawa K, Yasuda K, Amaha K. [Effects of thiopental and sevoflurane on hemodynamics during anesthetic management of electroconvulsive therapy]. Masui. 1997; 46:1575–9. Japanese.

60. Trzepacz PT, Weniger FC, Greenhouse J. Etomidate anesthesia increases seizure duration during ECT. A retrospective study. Gen Hosp Psychiatry. 1993; 15:115–20.

61. Eranti SV, Mogg AJ, Pluck GC, Landau S, McLoughlin DM. Methohexitone, propofol and etomidate in electroconvulsive therapy for depression: a naturalistic comparison study. J Affect Disord. 2009; 113:165–71.

62. Fredman B, d'Etienne J, Smith I, Husain MM, White PF. Anesthesia for electroconvulsive therapy: effects of propofol and methohexital on seizure activity and recovery. Anesth Analg. 1994; 79:75–9.

63. Geretsegger C, Rochowanski E, Kartnig C, Unterrainer AF. Propofol and methohexital as anesthetic agents for electroconvulsive therapy (ECT): a comparison of seizure-quality measures and vital signs. J ECT. 1998; 14:28–35.

64. Bailine SH, Petrides G, Doft M, Lui G. Indications for the use of propofol in electroconvulsive therapy. J ECT. 2003; 19:129–32.

65. Fear CF, Littlejohns CS, Rouse E, McQuail P. Propofol anaesthesia in electroconvulsive therapy. Reduced seizure duration may not be relevant. Br J Psychiatry. 1994; 165:506–9.

66. Parashchanka A, Schelfout S, Coppens M. Role of novel drugs in sedation outside the operating room: dexmedetomidine, ketamine and remifentanil. Curr Opin Anaesthesiol. 2014; 27:442–7.

67. Kavalali ET, Monteggia LM. How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol. 2015; 20:35–9.

68. Boylan LS, Haskett RF, Mulsant BH, Greenberg RM, Prudic J, Spicknall K, et al. Determinants of seizure threshold in ECT: benzodiazepine use, anesthetic dosage, and other factors. J ECT. 2000; 16:3–18.

69. Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020; 33:506–11.

70. Mizrak A, Koruk S, Ganidagli S, Bulut M, Oner U. Premedication with dexmedetomidine and midazolam attenuates agitation after electroconvulsive therapy. J Anesth. 2009; 23:6–10.

71. Qiu Z, Zhou S, Zhang M, Guo N, Huang P, Xiang P, et al. Preventive effect of dexmedetomidine on postictal delirium after electroconvulsive therapy: a randomised controlled study. Eur J Anaesthesiol. 2020; 37:5–13.

72. Ishikawa T, Kawahara S, Saito T, Otsuka H, Kemmotsu O, Hirayama E, et al. [Anesthesia for electroconvulsive therapy during pregnancy--a case report]. Masui. 2001; 50:991–7. Japanese.

73. Fink M, Bailine S. Electroconvulsive therapy and managed care. Am J Manag Care. 1998; 4:107–12. quiz 113-4.

74. Fredman B, Smith I, d'Etienne J, White PF. Use of muscle relaxants for electroconvulsive therapy: how much is enough? Anesth Analg. 1994; 78:195–6.

75. Tang WK, Ungvari GS. Asystole during electroconvulsive therapy: a case report. Aust N Z J Psychiatry. 2001; 35:382–5.

76. Cooper RC, Baumann PL, McDonald WM. An unexpected hyperkalemic response to succinylcholine during electroconvulsive therapy for catatonic schizophrenia. Anesthesiology. 1999; 91:574–5.

77. Jaksa RJ, Palahniuk RJ. Attempted organophosphate suicide: a unique cause of prolonged paralysis during electroconvulsive therapy. Anesth Analg. 1995; 80:832–3.

78. Kelly D, Brull SJ. Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine? Can J Anaesth. 1994; 41:845–9.

79. Lui PW, Ma JY, Chan KK. Modification of tonic-clonic convulsions by atracurium in multiple-monitored electroconvulsive therapy. J Clin Anesth. 1993; 5:16–21.

80. Hickey DR, O'Connor JP, Donati F. Comparison of atracurium and succinylcholine for electroconvulsive therapy in a patient with atypical plasma cholinesterase. Can J Anaesth. 1987; 34:280–3.

81. Postaci A, Tiryaki C, Sacan O, Ornek D, Kalyoncu M, Dikmen B. Rocuronium-sugammadex decreases the severity of post-electroconvulsive therapy agitation. J ECT. 2013; 29:e2–3.

82. Wolkenstein K, Ali S, Chacko R, Nabi Q, Carter L. Rocuronium-sugammadex and intubation used for an electroconvulsive therapy patient. J ECT. 2020; 36:e15–6.

83. de Boer HD, Carlos RV. New drug developments for neuromuscular blockade and reversal: gantacurium, CW002, CW011, and Calabadion. Curr Anesthesiol Rep. 2018; 8:119–24.

84. Weinger MB, Partridge BL, Hauger R, Mirow A, Brown M. Prevention of the cardiovascular and neuroendocrine response to electroconvulsive therapy: II. Effects of pretreatment regimens on catecholamines, ACTH, vasopressin, and cortisol. Anesth Analg. 1991; 73:563–9.

85. Saito S. Anesthesia management for electroconvulsive therapy: hemodynamic and respiratory management. J Anesth. 2005; 19:142–9.

86. Kelway B, Simpson KH, Smith RJ, Halsall PJ. Effects of atropine and glycopyrrolate on cognitive function following anaesthesia and electroconvulsive therapy (ECT). Int Clin Psychopharmacol. 1986; 1:296–302.

87. Avramov MN, Stool LA, White PF, Husain MM. Effects of nicardipine and labetalol on the acute hemodynamic response to electroconvulsive therapy. J Clin Anesth. 1998; 10:394–400.

88. O'Flaherty D, Husain MM, Moore M, Wolff TR, Sills S, Giesecke AH. Circulatory responses during electroconvulsive therapy. The comparative effects of placebo, esmolol and nitroglycerin. Anaesthesia. 1992; 47:563–7.

89. Parab AL, Chaudhari LS, Apte J. Use of nitroglycerin ointment to prevent hypertensive response during electroconvulsive therapy--a study of 50 cases. J Postgrad Med. 1992; 38:55–7.

90. Villalonga A, Planella T, Castillo J, Hernández C, Cabrer C, Mañalich M, et al. [Nitroglycerin spray in the prevention of hypertension induced by electroconvulsive therapy]. Rev Esp Anestesiol Reanim. 1989; 36:264–6. Spanish.

91. Devanand DP, Malitz S, Sackeim HA. ECT in a patient with aortic aneurysm. J Clin Psychiatry. 1990; 51:255–6.

92. Drop LJ, Bouckoms AJ, Welch CA. Arterial hypertension and multiple cerebral aneurysms in a patient treated with electroconvulsive therapy. J Clin Psychiatry. 1988; 49:280–2.

93. Levin L, Wambold D, Viguera A, Welch CA, Drop LJ. Hemodynamic responses to ECT in a patient with critical aortic stenosis. J ECT. 2000; 16:52–61.

94. Sudha S, Andrade C, Anand A, Guido S, Venkataraman BV. Nitroprusside and ECS-induced retrograde amnesia. J ECT. 2001; 17:41–4.

95. Petrides G, Maneksha F, Zervas I, Carasiti I, Francis A. Trimethaphan (Arfonad) control of hypertension and tachycardia during electroconvulsive therapy: a double-blind study. J Clin Anesth. 1996; 8:104–9.

96. Fu W, Stool LA, White PF, Husain MM. Acute hemodynamic responses to electroconvulsive therapy are not related to the duration of seizure activity. J Clin Anesth. 1997; 9:653–7.

97. MacPherson R, Marroquin-Harris M, Gálvez V, Tor P, Loo C. The effect of adjuvant remifentanil with propofol or thiopentone on seizure quality during electroconvulsive therapy. Anaesth Intensive Care. 2016; 44:278–80.

98. Akcaboy ZN, Akcaboy EY, Yigitbasł B, Bayam G, Dikmen B, Gogus N, et al. Effects of remifentanil and alfentanil on seizure duration, stimulus amplitudes and recovery parameters during ECT. Acta Anaesthesiol Scand. 2005; 49:1068–71.

99. Andersen FA, Arsland D, Holst-Larsen H. Effects of combined methohexitone-remifentanil anaesthesia in electroconvulsive therapy. Acta Anaesthesiol Scand. 2001; 45:830–3.

100. Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth. 2020; 124:44–62.

101. van Zijl DH, Gordon PC, James MF. The comparative effects of remifentanil or magnesium sulfate versus placebo on attenuating the hemodynamic responses after electroconvulsive therapy. Anesth Analg. 2005; 101:1651–5.

102. Park MJ, Kim H, Kim EJ, Yook V, Chung IW, Lee SM, et al. Recent updates on electro-convulsive therapy in patients with depression. Psychiatry Investig. 2021; 18:1–10.

103. Osler M, Rozing MP, Christensen GT, Andersen PK, Jørgensen MB. Electroconvulsive therapy and risk of dementia in patients with affective disorders: a cohort study. Lancet Psychiatry. 2018; 5:348–56.

104. Tzabazis A, Schmitt HJ, Ihmsen H, Schmidtlein M, Zimmermann R, Wielopolski J, et al. Postictal agitation after electroconvulsive therapy: incidence, severity, and propofol as a treatment option. J ECT. 2013; 29:189–95.